Albirus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 5 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 1.90 M
- Revenue Growth %
- Profit Growth 150.53%
- Ebitda 278.27%
- Net Worth 25.76%
- Total Assets 992.99%
About Albirus Pharmaceuticals
Albirus Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 September 2018 (Six years and five months 8 days old ). Its registered office is in Cuttack, Odisha, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.90 M.
Amit Sinha and Upasana Sinha serve as directors at the Company.
Company Details
-
Location
Cuttack, Odisha, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51909OR2018PTC029428
-
Company No.
029428
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Sep 2018
-
Date of AGM
15 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Albirus Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amit Sinha
|
Director | 08-Sep-2018 | Current |
|
Upasana Sinha
|
Director | 16-Jan-2024 | Current |
Financial Performance of Albirus Pharmaceuticals.
Albirus Pharmaceuticals Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 150.53% increase in profit. The company's net worth Soared by an impressive increase of 25.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Albirus Pharmaceuticals?
In 2020, Albirus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Debarati Agro Foods Private LimitedAmit Sinha and Upasana Sinha are mutual person
-
Climax Infratech And Logistics Private Limited
Amit Sinha is a mutual person
Charges (Loans)
₹1.90 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.10 Cr
- Others : 0.09 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Apr 2024 | Canara Bank | ₹1.00 M | Open |
| 30 Aug 2021 | Others | ₹0.90 M | Open |
How Many Employees Work at Albirus Pharmaceuticals?
Unlock and access historical data on people associated with Albirus Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Albirus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Albirus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
